drugset
drugset / Trial / NCT05626439

A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants

NCT05626439 ↗

Phase 1 Completed 21 enrolled UCB Biopharma SRL
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of the study is to evaluate the relative bioavailability of alprazolam in plasma following a single dose of Staccato alprazolam compared to a single dose of oral alprazolam under fasted conditions

Timeline

Start
2022-12-28
Primary completion
2023-02-24
Completion
2023-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Alprazolam Small molecule — Inhaled
Subject Alprazolam Small molecule — Oral

Indications

No indication recorded.